COVID-19: Providers

Monoclonal Antibodies and Other Outpatient Therapeutics

There are several COVID-19 oral antivirals under development, but anti-SARS-CoV-2 monoclonal antibodies are currently the only therapeutic authorized for:

  • Treatment of non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.
  • Post-exposure prophylaxis (PEP) for people at high risk of progressing to severe COVID-19.

Monoclonal antibodies are made in a laboratory and work as substitute antibodies that can help fight an infection before the body mounts its own immune response. The antibodies are directed against specific targets on the spike protein of SARS-CoV-2, blocking viral entry into cells. They are recommended by the National Institutes of Health COVID-19 Treatment Guidelines for outpatient treatment of COVID-19 and post-exposure prophylaxis (PEP).

If you start treatment soon after the onset of symptoms, monoclonal antibodies can decrease the risk of hospitalization and death due to COVID-19 by as much as 70% to 85% and reduce hospital length of stay and emergency department visits.

As PEP, the antibodies can reduce the risk of developing symptomatic COVID-19 by 80%.

Providers should refer all eligible symptomatic patients for this treatment, regardless of a patient's vaccination status.


Available Products

Clinical Considerations

To decide if monoclonal antibody therapy is appropriate for a patient, refer to the Monoclonal Antibody Therapy Decision Support Tool for Health Care Providers (PDF).

Treatment is most effective when given soon after symptom onset and should be considered for eligible patients, regardless of vaccination status.

For PEP, there is no optimal timing stated in the emergency use authorization. Clinical trials evaluating their efficacy included patients within 96 hours of exposure.

Referring or Offering Monoclonal Antibody Therapy

Referring for Therapy

Here are some resources to help you find a referral site:

Offering Therapy

The following websites have information for providers interested in offering monoclonal antibody therapy:

Patient Education

People at increased risk of severe COVID-19 and their caregivers should be advised:

  • About the benefits of prompt monoclonal antibody therapy to reduce the risk of hospitalization and death
  • To immediately get tested if they develop COVID-19 symptoms
  • To contact their provider right away if they test positive or suspect they were exposed to COVID-19

Resources for Patients

Additional Resources